Monashee Investment Management LLC Argenx Se Transaction History

Monashee Investment Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$338.91 - $506.01 $847,275 - $1.27 Million	2,500 Added 33.33%	10,000 $3.8 Million
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $923,375 - $1.37 Million	-2,500 Reduced 25.0%	7,500 $3.69 Million
Q1 2023 May 05, 2023	BUY	$334.23 - $403.65 $3.34 Million - $4.04 Million	10,000 New	10,000 $3.73 Million
Q3 2022 Nov 01, 2022	BUY	$343.2 - $395.75 $4.12 Million - $4.75 Million	12,000 New	12,000 $4.24 Million
Q3 2020 Nov 13, 2020	SELL	$215.51 - $272.51 $3.23 Million - $4.09 Million	-15,000 Closed	0 $0
Q2 2020 Aug 11, 2020	BUY	$127.44 - $232.72 $1.91 Million - $3.49 Million	15,000 New	15,000 $3.38 Million
Q1 2018 May 10, 2018	SELL	$56.95 - $85.19 $3.19 Million - $4.77 Million	-56,000 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$22.57 - $63.56 $1.26 Million - $3.56 Million	56,000	56,000 $3.54 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Monashee Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Monashee Investment Management LLC with notifications on news.